查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1845905

全球兹卡疫苗市场规模（按疫苗类型、应用、区域范围和预测）

Global Zika Vaccines Market Size By Vaccine Type(Inactivated Vaccine, Purified Inactivated Vaccine, DNA Vaccine), By Application (Clinics, Academic and Research, Hospitals), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

兹卡疫苗市场规模及预测

预计兹卡疫苗市场在 2024 年的价值将达到 136.91 亿美元，并在 2031 年达到 197.89 亿美元，2024 年至 2031 年的复合年增长率为 5.4%。

兹卡病毒在各国的感染疾病不断上升，推动了全球寨卡疫苗市场的发展。大型製药公司正在加大对新疫苗研发的投入，从而推动全球市场的扩张。此外，不断加强的推广宣传活动以及与世界卫生组织在疫苗研发方面的合作研究也推动了寨卡疫苗市场的成长。全球兹卡疫苗市场报告对市场进行了全面的评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

兹卡疫苗的全球市场定义

兹卡病毒（ZIKV），又称黄病毒，属于黄病毒科，是一种蚊媒感染疾病，可透过蚊子、输血、性接触以及受感染的孕妇传播给婴儿。蚊子兹卡病毒，并将病毒传播给叮咬者。兹卡病毒感染可导致胎儿神经系统异常和先天性畸形。目前，兹卡病毒疫苗正在研发中，用于预防和控制兹卡病毒引起的疾病。

目前用于预防兹卡病毒的疫苗种类繁多，包括mRNA疫苗、DNA疫苗和灭活疫苗。该病毒也可由受感染的孕妇传播给胎儿。 PCR检测可用于诊断感染。然而，只有四分之一的感染者会出现症状。 2016年11月，世界卫生组织（WHO）宣布兹卡病毒不再构成公共卫生威胁。然而，由于大多数病例无症状，该病毒仍然受到国际社会关注。

全球兹卡疫苗市场概览

兹卡病毒活跃病例的不断增加以及兹卡病毒对其影响日益增长的担忧，是推动寨卡疫苗市场发展和全球兹卡病毒疫苗需求成长的主要因素。兹卡病毒的日益流行正刺激有效疫苗的生产。大众对病毒认识的提高鼓励了这些疫苗的使用，从而推动了市场的发展。疫苗研发投入的不断增加以及政府政策的推出也推动了兹卡疫苗市场的成长。

此外，兹卡病毒需求的不断增长以及疫苗技术的进步也有望促进业务成长和发展。然而，限制市场成长和发展的因素包括价格昂贵以及偏远地区民众对疫苗的认知度和认可度较低。低度开发国家对先进技术的使用缺乏了解也限制了市场的成长。此外，这些疫苗可能对人体产生一些有害影响，这反过来又可能抑制市场成长。

目录

第一章 全球兹卡疫苗市场简介

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章：已验证的市场调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概况
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球寨卡疫苗市场区域分析
  • 全球兹卡疫苗市场（按疫苗类型划分）（百万美元）
  • 全球寨卡疫苗市场应用情形（百万美元）
  • 未来市场机会
  • 世界市场结构
  • 产品生命线

第四章 全球兹卡疫苗市场展望

  • 全球兹卡疫苗的演变
  • 驱动程式
    • 司机1
    • 司机2
  • 阻碍因素
    • 阻碍因素1
    • 阻碍因素2
  • 机会
    • 机会 1
    • 机会 2
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

第五章全球兹卡疫苗市场（依疫苗类型）

  • 概述
  • 灭活疫苗
  • 纯化灭活疫苗
  • DNA疫苗

第六章 全球兹卡疫苗市场（按应用）

  • 概述
  • 诊所
  • 学术和研究机构
  • 医院
  • 其他的

第七章全球兹卡疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第八章全球兹卡疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要进展
  • 公司地理分布
  • 公司产业足迹
  • ACE矩阵

第九章：公司简介

  • Inovio Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • Gilead Sciences Inc
  • Precigen Inc
  • LUMOS PHARMA
  • Hawaii Biotech Inc
  • Sanofi
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Bharat Biotech

第 10 章：经过验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 39420

Zika Vaccines Market Size And Forecast

Zika Vaccines Market size was valued at USD 13,691 Million in 2024 and is projected to reach USD 19,789 Million by 2031, growing at a CAGR of 5.4% from 2024 to 2031.

The increased prevalence of Zika virus disease in countries is driving the global Zika Vaccines Market forward. Major pharmaceutical companies that have increased the investment in R&D for the production of new vaccines is driving the global market's expansion. In addition, there has been an increase in outreach campaigns and a partnership study for vaccine development with the World Health Organization which is driving the growth of Zika Vaccines Market. The Global Zika Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Zika Vaccines Market Definition

Zika virus (ZIKV), also known as a flavivirus, that is from the Flaviviridae family, is a mosquito-borne disease that spreads to humans through mosquitos, blood transfusions, sex, and from an infected pregnant woman to her baby. After biting a zika-infected human, a mosquito becomes infected with the virus and spreads it to anyone they sting. Infection with the Zika virus may result in neurological abnormalities and congenital birth defects in the fetus. Zika vaccines are being designed to help people prevent and manage diseases caused by the Zika virus.

There are many varieties of vaccines used to protect against the Zika virus, including mRNA vaccines, DNA vaccines, and inactivated vaccines. In addition, the virus can be transmitted from an infected pregnant woman to her fetus. PCR is used for the diagnosis of the infection. However, only 1 out of every 4 people with the virus has the risk of developing symptoms. In November 2016, the World Health Organization (WHO) announced that the Zika virus is no longer a threat to public health, which has been an international concern since the major cases of the virus are asymptomatic.

Global Zika Vaccines Market Overview

The increasing prevalence of the active Zika virus as well as increased concern about the consequences of the Zika virus has increased the market for Zika vaccines and is the primary factor driving the global Zika virus vaccine demand. The rising prevalence of Zika fever is fueling the production of effective vaccines. The growing public understanding of the virus is encouraging the use of these vaccines which in turn is driving the market. Increased investment in vaccine research and development, as well as favorable government policies, are also the growth drivers for the Zika Vaccines Market.

In addition, the increase in demand for zika virus and advancements in vaccine technologies are expected to help in business growth and development. However, the factors restraining the market growth and development are a lack of affordability and a lack of recognition and awareness in remote areas. Also, the lack of knowledge in using advanced technology in underdeveloped countries is also restraining the market growth. In addition, these vaccines might cause some harmful effects on the body of individuals which in turn can restrain the market growth.

Global Zika Vaccines Market: Segmentation Analysis

The Global Zika Vaccines Market is segmented based on Vaccine Type, Application, and Geography.

Zika Vaccines Market, By Vaccine Type

Inactivated Vaccine

Purified Inactivated Vaccine

DNA Vaccine

Based on Vaccine Type, the market is bifurcated into Inactivated Vaccine, Purified Inactivated Vaccine, and DNA Vaccine. Inactivated Vaccine dominated the market in 2019 and is likely to continue in the forecast period. Purified Inactivated Vaccine has good market potentials in the forecast period owing to the evolution of modern medicines and equipment technologies.

Zika Vaccines Market, By Application

Clinics

Academic and Research

Hospitals

Others

Based on Application, the market is bifurcated into Clinics, Academic and Research, Hospitals, and Others. The hospital segment accounted for the strongest share in 2019, and this pattern is expected to continue. An increase in patients with Zika virus disease would necessitate hospitalization. Also, the early availability of new drugs in hospitals is expected to fuel the segment's development.

Zika Vaccines Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on regional analysis, the Global Zika Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In 2019, the Rest of the world led the global Zika Vaccines Market, and this pattern is projected to continue over the years. The region's domination can be due to a rise in people infected with the Zika virus in countries such as Brazil, Bolivia, and Peru, as well as the involvement of major players.

Key Players

The "Global Zika Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Inovio Pharmaceuticals, Inc., Emergent BioSolutions Inc., Gilead Sciences Inc., Precigen, Inc., LUMOS PHARMA, Hawaii Biotech Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, and Bharat Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Zika Vaccines market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in global Zika Vaccines market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ZIKA VACCINES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Zika Vaccines Market Geographical Analysis (CAGR %)
  • 3.6 Global Zika Vaccines Market, By Vaccine Type (USD Million)
  • 3.7 Global Zika Vaccines Market, By Application (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL ZIKA VACCINES MARKET OUTLOOK

  • 4.1 Global Zika Vaccines Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL ZIKA VACCINES MARKET, BY VACCINE TYPE

  • 5.1 Overview
  • 5.2 Inactivated Vaccine
  • 5.3 Purified Inactivated Vaccine
  • 5.4 DNA Vaccine

6 GLOBAL ZIKA VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Clinics
  • 6.3 Academic and Research
  • 6.4 Hospitals
  • 6.5 Others

7 GLOBAL ZIKA VACCINES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL ZIKA VACCINES MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Inovio Pharmaceuticals Inc
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Emergent BioSolutions Inc
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Gilead Sciences Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Precigen Inc
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 LUMOS PHARMA
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Hawaii Biotech Inc
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Sanofi
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 GlaxoSmithKline plc
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Takeda Pharmaceutical Company Limited
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Bharat Biotech
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization